Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 3, 2019
Reporting Period: Single event date (July 3, 2019)
Business Context: The filing serves as a Regulation FD disclosure regarding a press release issued on July 3, 2019. The release announced that R.J. Tesi, M.D., the Company's co-founder and Chief Executive Officer, presented at the Maxim Group's conference on Alzheimer's disease held on June 26, 2019, in New York City.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document solely discloses the occurrence of a conference presentation by the CEO.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the CEO's presentation at an Alzheimer's disease conference. The text of the presentation or specific outlook provided therein is not included in the body of this 8-K.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the text of this filing beyond the standard regulatory disclosures.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) to understand the specific details of the CEO's presentation at the Maxim Group conference.
- Confirm the company's status as an "emerging growth company" as indicated in the filing.
- Note that the press release is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Review subsequent filings for any financial impact or strategic updates resulting from the conference presentation.